Number of Adverse Events (AEs) and Serious Adverse Events (SAEs);Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity;Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment;Number of Participants With Pre-Specified Infusion Associated Adverse Events;Number of Subjects With Serious Adverse Events by 31 Days After First Infusion;Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90;Subjects With Adverse Events and Serious Adverse Events by Severity;Subjects With Adverse Events by Relatedness to Treatment

Number of Adverse Events (AEs) and Serious Adverse Events (SAEs);Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity;Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment;Number of Participants With Pre-Specified Infusion Associated Adverse Events;Number of Subjects With Serious Adverse Events by 31 Days After First Infusion;Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90;Subjects With Adverse Events and Serious Adverse Events by Severity;Subjects With Adverse Events by Relatedness to Treatment

Incidence of pre-specified infusion associated adverse events;Incidence of Severe Adverse Events

Incidence of pre-specified infusion associated adverse events;Incidence of Severe Adverse Events